Cynata Therapeutics Limited announced that the first patient in Cohort B has been treated with CYP-001, the Company’s first mesenchymal stem cell (MSC) product for steroid-resistant acute graft-versus-host disease (GvHD). Key Highlights:First patient with steroid-resistant acute GvHD treated in second cohort (Cohort B) in Cynata’s phase 1 clinical study of its Cymerus™ MSC product, CYP-001; Follows encouraging safety and efficacy data from the first patient cohort, and recommendation from the Data and Safety Monitoring Board (DSMB) to commence Cohort B, announced on 22 January. CYP-001 is manufactured in a scalable process using Cynata’s Cymerus platform with induced pluripotent stem cells (iPSCs) as the starting material. The Cymerus process overcomes both the need to source multiple donors and the inherent variability in products derived from multiple donations. Cynata is an industry leader with a sustainable and robust manufacturing process for therapeutic MSC products. While GvHD is the focus of the current clinical trial, Cynata continues to actively explore additional high-potential target diseases, including asthma, heart attack, brain cancer, and others. Phase 1 Clinical Trial and Next Steps - Following the advice from the Data and Safety Monitoring Board (DSMB) (as announced by the Company on 22 January), the trial resumed at seven major transplant centres in the UK and Australia. Patients in Cohort B will receive two infusions of CYP-001 one week apart, each at a dose of two million cells/kg, up to a maximum dose of 200 million cells. This is twice (2x) the dose level received by patients in Cohort A. A total of 8 patients are expected to participate in Cohort B; when combined with the 8 patients already treated in Cohort A, this makes a total of 16 patients in the phase 1 trial. Commencement of the second patient cohort (Cohort B) signifies advancement toward completion of the trial, expected later in 2018.